R&D — Equinox Group

R&D Insights

Featured

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Feb 10, 2026

R&D Insights

Finding the Best R&D Opportunities

Jan 27, 2026

R&D Insights

Finding the Best R&D Opportunities

Jan 27, 2026

R&D Insights

Jan 27, 2026

R&D Insights

Measuring Risk in R&D

Dec 29, 2025

R&D Insights

Measuring Risk in R&D

Dec 29, 2025

R&D Insights

Dec 29, 2025

R&D Insights

How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC

Nov 11, 2025

Oncology, R&D Insights

How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC

Nov 11, 2025

Oncology, R&D Insights

Nov 11, 2025

Oncology, R&D Insights

Screenshot 2025-10-30 154345.png

Oct 30, 2025

Oncology, R&D Insights

What indications should we focus on?

Oct 30, 2025

Oncology, R&D Insights

Oct 30, 2025

Oncology, R&D Insights

Two indications.PNG

Aug 26, 2020

Oncology, R&D Insights

Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study

Aug 26, 2020

Oncology, R&D Insights

Aug 26, 2020

Oncology, R&D Insights

Bubble chart.JPG

Apr 2, 2020

Oncology, R&D Insights

Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda

Apr 2, 2020

Oncology, R&D Insights

Apr 2, 2020

Oncology, R&D Insights

Jun 5, 2019

Oncology, R&D Insights

How to Price an Oncology Drug

Jun 5, 2019

Oncology, R&D Insights

Jun 5, 2019

Oncology, R&D Insights